Key Takeaway: Kyverna Therapeutics has reported significant progress in its pipeline, particularly with miv-cel, which has received RMAT designation from the FDA for non-active secondary progressive multiple sclerosis. This designation is based on compelling clinical data, indicating a promising future for the therapy in neuroimmunology. Additionally, the company is on track to complete its rolling BLA submission for miv-cel in stiff person syndrome by the end of Q4.
Market Sentiment Analysis
POSITIVE FACTORS
FDA granted RMAT designation for miv-cel in naSPMS.
Compelling clinical data supports miv-cel's potential.
Rolling BLA submission for miv-cel in SPS is on track.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
5%
average across 6 past catalysts
Cash runway
~15 mo
Low dilution risk
Lead asset
KYV-101 anti-CD19 CAR-T cell therapy
Phase 1 · Multiple Sclerosis
Full Press Release Details
FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4
Frequently Asked Questions
What designation did miv-cel receive from the FDA?
Miv-cel received RMAT designation for non-active secondary progressive multiple sclerosis.
What is the significance of RMAT designation?
RMAT designation indicates potential for expedited development and review for therapies.
When is the BLA submission for miv-cel expected?
The rolling BLA submission for miv-cel in stiff person syndrome is on track for Q4.
What condition does miv-cel target?
Miv-cel targets non-active secondary progressive multiple sclerosis and stiff person syndrome.